Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Brief Summary: This randomized, multicenter, open-label study will evaluate the safety and efficacy of DNIB0600A (RO5541081) in comparison with PLD in participants with PROC, primary peritoneal cancer or fallopian tube cancer. Participants will be randomized to receive either DNIB0600A 2.4 milligrams per kilogram (mg/kg) intravenously (IV) every 3 weeks or PLD 40 milligrams per meter-squared (mg/m\^2) IV every 4 weeks.


Options:
A: Arm Label: BI 6727; Type: EXPERIMENTAL; Interventions: Drug: BI 6727 | Arm Label: Cytotoxic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Gemcitabine, Drug: Topotecan, Drug: Pegylated liposomal doxorubicin (PLD) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: BI 6727; Assigned to Arm(s): BI 6727
B: Arm Label: Arm I (adjuvant chemotherapy suboptimally debulked); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Procedure: Computed Tomography, Drug: Paclitaxel, Procedure: Therapeutic Conventional Surgery | Arm Label: Arm II (neoadjuvant chemotherapy); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Procedure: Computed Tomography, Drug: Paclitaxel, Procedure: Therapeutic Conventional Surgery | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy)
C: Arm Label: DNIB0600A; Type: EXPERIMENTAL; Interventions: Drug: DNIB0600A | Arm Label: PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: PLD | Intervention Type: DRUG; Name: DNIB0600A; Assigned to Arm(s): DNIB0600A | Intervention Type: DRUG; Name: PLD; Assigned to Arm(s): PLD
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C